Assenagon Asset Management
BBIO icon

Assenagon Asset Management’s BridgeBio Pharma BBIO Stock Holding History

Assenagon Asset Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.16M Sell
15,620
-28,472
-65% -$1.99M ﹤0.01% 950
2026
Q1 		$3.27M Buy
44,092
+10,579
+32% +$767K 0.01% 676
2025
Q4 		$2.56M Sell
33,513
-225,391
-87% -$14.8M ﹤0.01% 792
2025
Q3 		$13.4M Sell
258,904
-91,507
-26% -$4.46M 0.02% 425
2025
Q2 		$15.1M Sell
350,411
-770,522
-69% -$28M 0.02% 393
2025
Q1 		$38.8M Buy
1,120,933
+1,096,799
+4,545% +$37M 0.06% 245
2024
Q4 		$662K Hold
24,134
– – ﹤0.01% 1161
2024
Q3 		$614K Sell
24,134
-222,761
-90% -$5.85M ﹤0.01% 1213
2024
Q2 		$6.25M Buy
246,895
+239,900
+3,430% +$6.56M 0.01% 563
2024
Q1 		$216K Sell
6,995
-29,739
-81% -$1.01M ﹤0.01% 1331
2023
Q4 		$1.48M Sell
36,734
-4,024
-10% -$121K ﹤0.01% 1013
2023
Q3 		$1.07M Sell
40,758
-110,204
-73% -$3.13M ﹤0.01% 1025
2023
Q2 		$2.6M Buy
150,962
+17,438
+13% +$262K 0.01% 682
2023
Q1 		$2.21M Sell
133,524
-102,676
-43% -$1.2M 0.01% 802
2022
Q4 		$1.8M Sell
236,200
-863
-0.4% -$8.26K 0.01% 845
2022
Q3 		$2.36M Sell
237,063
-252,270
-52% -$2.62M 0.01% 657
2022
Q2 		$4.44M Sell
489,333
-745,544
-60% -$6.24M 0.02% 581
2022
Q1 		$12.5M Buy
1,234,877
+1,223,122
+10,405% +$12.6M 0.03% 312
2021
Q4 		$196K Buy
11,755
+3,686
+46% +$156K ﹤0.01% 1377
2021
Q3 		$378K Buy
+8,069
New +$433K ﹤0.01% 1111

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Assenagon Asset Management's BBIO Position: Q2 2026 in Review

Assenagon Asset Management reduced its BridgeBio Pharma (BBIO) stake by 65% in Q2 2026, selling an estimated $1.99M and leaving 15,620 shares worth $1.16M. The position accounts for ﹤0.01% of the portfolio, ranked #950.

Assenagon Asset Management first reported a position in BBIO in Q3 2021 and has held it in 20 quarters since. The position peaked at $38.8M in Q1 2025. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Assenagon Asset Management held 15,620 shares of BridgeBio Pharma worth $1.16M as of Q2 2026.
  • Assenagon Asset Management sold 28,472 BridgeBio Pharma shares in Q2 2026, an estimated $1.99M.
  • BridgeBio Pharma made up ﹤0.01% of Assenagon Asset Management's portfolio in Q2 2026, its #950 holding.
  • Assenagon Asset Management first reported a position in BridgeBio Pharma in Q3 2021 and has held it in 20 quarters since.
  • Assenagon Asset Management's BridgeBio Pharma position peaked at $38.8M in Q1 2025.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Assenagon Asset Management's 13F filing for Q2 2026, filed 8 Jul 2026.